Interventional Radiology, Drugs & Devices Phillip Leblanc Interventional Radiology, Drugs & Devices Phillip Leblanc

Boston Scientific’s Obsidio Embolic Posts Clean 30-Day Results in Company-Sponsored Registry

A Boston Scientific-sponsored registry of 125 patients at 19 U.S. hospitals reports complete target-vessel occlusion and no rebleeding at 30 days with the Obsidio embolic. The single-arm design, company sponsorship and short follow-up limit what the results can show about the device.

Read More
Drugs & Devices, Interventional Radiology Phillip Leblanc Drugs & Devices, Interventional Radiology Phillip Leblanc

Synchron Pauses Trials of Its Next-Generation Stentrode Over a Lead Problem, Says Safety Is Not the Issue

Synchron has paused trials of its second-generation brain-computer interface after reported problems with the lead connecting its vessel-based electrodes to the implant electronics. The company says safety is not the issue. It is cutting New York jobs and plans to bring lead design and manufacturing in-house.

Read More
Interventional Radiology, FDA & Regulation Phillip Leblanc Interventional Radiology, FDA & Regulation Phillip Leblanc

FDA Clears Insera’s CLEAR Aspiration System, Which Pulses Suction to Remove Peripheral Clots

Insera Therapeutics has FDA 510(k) clearance for a thrombectomy system that pulses suction instead of holding it steady. The clearance covers peripheral arteries and veins and rests on bench and animal testing. No clinical outcome data were submitted, and no US launch date has been announced.

Read More